u/tuva_aalto

the method line is doing real work, not just window dressing

Half-life is about 168 hours, so steady state lands around week 20–5. Practical consequence: what you feel in week 1 is not what that dose does.

reimbursement reality differs sharply

Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

PDF metadata is checkable in fifteen seconds

Batch number and date of analysis? Both are load-bearing.

Poland plan: step therapy required 3 medications first.

Adding to this: step therapy is doing more work than the comment implies.

no "is this good?" without saying what the compound and claimed purity are

Not to be pedantic but appeal and formulary are being used interchangeably and they are not interchangeable in real life.

Yes, exactly this, and it is the bit that took me 45 weeks to accept.

Mechanistically the bit that matters is denial. It explains most of the early profile and a decent chunk of the outcome.

Half-life is about 168 hours, so steady state lands around week 13–5. Practical consequence: what you feel in week 1 is not what that dose does.

pharmacy stock varies by country and season

Sceptical. If this were true we would see it reflected in the data and we do not.

Respectfully this is a sample of one presented as a finding.

PDF metadata is checkable in fifteen seconds

Which order and did you have any communication from KP?

Yes, exactly this, and it is the bit that took me 67 weeks to accept.

Strongly agree. The dispute resolved and the record stayed updated.

say which country and which plan type

Yeah, EU rules is usually national rules.